CVE:RVV - Revive Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$0.10 -0.01 (-5.00 %)
(As of 01/21/2019 04:00 PM ET)
Previous CloseC$0.10
Today's RangeC$0.09 - C$0.10
52-Week RangeC$0.09 - C$0.44
Volume29,007 shs
Average Volume101,637 shs
Market CapitalizationN/A
P/E Ratio-3.28
Dividend YieldN/A
BetaN/A
Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.

Receive RVV News and Ratings via Email

Sign-up to receive the latest news and ratings for RVV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone+1-905-6055535

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.01 per share
Book ValueC$0.01 per share

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

Revive Therapeutics (CVE:RVV) Frequently Asked Questions

What is Revive Therapeutics' stock symbol?

Revive Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RVV."

How were Revive Therapeutics' earnings last quarter?

Revive Therapeutics Ltd (CVE:RVV) posted its quarterly earnings results on Wednesday, November, 28th. The company reported ($0.01) EPS for the quarter. View Revive Therapeutics' Earnings History.

When is Revive Therapeutics' next earnings date?

Revive Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Revive Therapeutics.

Has Revive Therapeutics been receiving favorable news coverage?

News articles about RVV stock have trended very positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Revive Therapeutics earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are some of Revive Therapeutics' key competitors?

Who are Revive Therapeutics' key executives?

Revive Therapeutics' management team includes the folowing people:
  • Mr. Craig Leon, Chairman & CEO (Age 51)
  • Mr. Fabio Chianelli, Pres & Director (Age 41)
  • Mr. Carmelo Marrelli C.A., C.P.A., CPA, B.Comm., CA, CGA, ACIS, Chief Financial Officer (Age 48)
  • Dr. Beverly J. Incledon, Vice-Pres of R&D (Age 51)
  • Dr. Ram Subramanian M.D., Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases

How do I buy shares of Revive Therapeutics?

Shares of RVV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Revive Therapeutics' stock price today?

One share of RVV stock can currently be purchased for approximately C$0.10.

What is Revive Therapeutics' official website?

The official website for Revive Therapeutics is http://www.revivethera.com/.

How can I contact Revive Therapeutics?

Revive Therapeutics' mailing address is 5 Director Crt Suite 105, WOODBRIDGE, ON L4L 4S5, Canada. The company can be reached via phone at +1-905-6055535.


MarketBeat Community Rating for Revive Therapeutics (CVE RVV)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  87
MarketBeat's community ratings are surveys of what our community members think about Revive Therapeutics and other stocks. Vote "Outperform" if you believe RVV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Featured Article: Backdoor Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel